BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 23416769)

  • 1. A comparison of cell-cycle markers in skull base and sacral chordomas.
    Yakkioui Y; Temel Y; Creytens D; Jahanshahi A; Fleischeuer R; Santegoeds RG; Van Overbeeke JJ
    World Neurosurg; 2014; 82(1-2):e311-8. PubMed ID: 23416769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the cell cycle in the pathophysiology of chordomas: a molecular look.
    Kaloostian PE; Gokaslan ZL
    World Neurosurg; 2014; 82(1-2):e135-7. PubMed ID: 23380279
    [No Abstract]   [Full Text] [Related]  

  • 3. Alterations of G1-S checkpoint in chordoma: the prognostic impact of p53 overexpression.
    Naka T; Boltze C; Kuester D; Schulz TO; Schneider-Stock R; Kellner A; Samii A; Herold C; Ostertag H; Roessner A
    Cancer; 2005 Sep; 104(6):1255-63. PubMed ID: 16078265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of immunohistochemical expression of p53 and the proliferation marker Ki-67 antigen in skull base chordomas: relationships between their expression and prognosis.
    Sakai K; Hongo K; Tanaka Y; Nakayama J
    Brain Tumor Pathol; 2007; 24(2):57-62. PubMed ID: 18095132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
    Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
    Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apoptotic and proliferative markers in chordomas: a study of 26 tumors.
    Kilgore S; Prayson RA
    Ann Diagn Pathol; 2002 Aug; 6(4):222-8. PubMed ID: 12170453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of ezrin, MMP-9, and COX-2 in 50 chordoma specimens: a clinical and immunohistochemical analysis.
    Froehlich EV; Scheipl S; Lazàry A; Varga PP; Schmid C; Stammberger H; Beham A; Bodo K; Schroettner H; Quehenberger F; Windhager R; Liegl B; Leithner A
    Spine (Phila Pa 1976); 2012 Jun; 37(13):E757-67. PubMed ID: 22228328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of the BMP4/SMAD signaling pathway in skull base chordomas is associated with poor prognosis.
    Feng Y; Zhang Q; Wang Z; Yan B; Wei W; Li P
    Int J Clin Exp Pathol; 2015; 8(7):8268-75. PubMed ID: 26339396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics, immunohistochemistry, and outcomes of 77 patients with skull base chordomas.
    Ouyang T; Zhang N; Zhang Y; Jiao J; Ren J; Huang T; Chen J
    World Neurosurg; 2014; 81(5-6):790-7. PubMed ID: 23298670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skull base chordoma and chondrosarcoma: influence of clinical and demographic factors on prognosis: a SEER analysis.
    Bohman LE; Koch M; Bailey RL; Alonso-Basanta M; Lee JY
    World Neurosurg; 2014 Nov; 82(5):806-14. PubMed ID: 25009165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
    Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
    Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocellular carcinoma--survival and clinical characteristics in relation to various histologic molecular markers in Western patients.
    Schöniger-Hekele M; Hänel S; Wrba F; Müller C
    Liver Int; 2005 Feb; 25(1):62-9. PubMed ID: 15698400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of cell-cycle-regulated proteins pRb2/p130, p107, p27(kip1), p53, mdm-2, and Ki-67 (MIB-1) in prostatic gland adenocarcinoma.
    Claudio PP; Zamparelli A; Garcia FU; Claudio L; Ammirati G; Farina A; Bovicelli A; Russo G; Giordano GG; McGinnis DE; Giordano A; Cardi G
    Clin Cancer Res; 2002 Jun; 8(6):1808-15. PubMed ID: 12060621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of the apoptotic index analysed jointly with selected cell cycle regulators and proliferation markers in non-small cell lung cancer.
    Dworakowska D; Jassem E; Jassem J; Karmoliński A; Lapiński M; Tomaszewski D; Rzyman W; Jaśkiewicz K; Sworczak K; Grossman AB
    Lung Cancer; 2009 Oct; 66(1):127-33. PubMed ID: 19200616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder.
    Yurakh AO; Ramos D; Calabuig-Fariñas S; López-Guerrero JA; Rubio J; Solsona E; Romanenko AM; Vozianov AF; Pellin A; Llombart-Bosch A
    Eur Urol; 2006 Sep; 50(3):506-15; discussion 515. PubMed ID: 16624482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome.
    Jarnagin WR; Klimstra DS; Hezel M; Gonen M; Fong Y; Roggin K; Cymes K; DeMatteo RP; D'Angelica M; Blumgart LH; Singh B
    J Clin Oncol; 2006 Mar; 24(7):1152-60. PubMed ID: 16505435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
    Sjöström J; Blomqvist C; Heikkilä P; Boguslawski KV; Räisänen-Sokolowski A; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Bergh J; Wist E; Valvere V; Saksela E
    Clin Cancer Res; 2000 Aug; 6(8):3103-10. PubMed ID: 10955790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of Raf-1 and ERK1/2 in sacral chordoma and association with tumor recurrence.
    Zhang K; Chen H; Zhang B; Sun J; Lu J; Chen K; Yang H
    Int J Clin Exp Pathol; 2015; 8(1):608-14. PubMed ID: 25755752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations of cell cycle regulators in localized synovial sarcoma: A multifactorial study with prognostic implications.
    Antonescu CR; Leung DH; Dudas M; Ladanyi M; Brennan M; Woodruff JM; Cordon-Cardo C
    Am J Pathol; 2000 Mar; 156(3):977-83. PubMed ID: 10702413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of EGFR, Hepatocyte Growth Factor Receptor (c-Met), c-ErbB2 (HER2-neu) and Clinicopathological Parameters in the Pathogenesis and Prognosis of Chordoma.
    Tosuner Z; Bozkurt SU; Kiliç T; Yilmaz B
    Turk Patoloji Derg; 2017; 33(2):112-120. PubMed ID: 28272674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.